To scale or not to scale: The principles of dose extrapolation

British Journal of Pharmacology

Volumn 157, Issue 6, 2009, Pages 907-921

  Sharma, Vijay ^a   McNeill, John H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Allometric scaling; Body surface area; Dose extrapolation; Paediatric dosing; Pharmacodynamics; Pharmacokinetics; Physiological time; Species difference

Indexed keywords

BILIARY EXCRETION; BODY MASS; BODY SURFACE; COMPUTER MODEL; DISTRIBUTION VOLUME; DOSE RESPONSE; DOSIMETRY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TRANSPORT; FIRST PASS EFFECT; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPECIES DIFFERENCE; URINARY EXCRETION; VETERINARY MEDICINE;

AGE FACTORS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, ANIMAL; PHARMACEUTICAL PREPARATIONS; PRACTICE GUIDELINES AS TOPIC; SPECIES SPECIFICITY;

EID: 70350348642     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00267.x     Document Type: Review

References (93)

1. Adolph EF (1949). Quantitative relations in the physiological constitutions of mammals. Science 109: 579-585.
2. Agutter PS, Wheatley DN (2004). Metabolic scaling: consensus or controversy? Theor Biol Med Model 1: 13.
3. Aitken MM (1983). Species differences in pharmacodynamics: some examples. Vet Res Commun 7: 313-324.
4. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A et al. (2006). Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337-342.
5. Bjorkman S (2005). Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol 59: 691-704.
6. Bjorkman S (2006). Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children: how accurate are available scaling methods? Clin Pharmacokinet 45: 1-11.
7. Blackwell B, Martz BL (1972). For the first time in man. Clin Pharmacol Ther 13: 812-826.
8. Bleasby K, Castle JC, Roberts CJ, Cheng C, Bailey WJ, Sina JF et al. (2006). Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica 36: 963-988.
9. Bokkers BG, Slob W (2007). Deriving a data-based interspecies assessment factor using the NOAEL and the benchmark dose approach. Crit Rev Toxicol 37: 355-373.
10. Bonate PL, Howard D (2000). Prospective allometric scaling: does the emperor have clothes? J Clin Pharmacol 40: 335-340.
11. Boxenbaum H (1982). Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10: 201-227.
12. Brody S (1945). Bioenergetics and Growth. Haffner: New York.
13. Brown JH, Gillooly AP, Allen VM, Savage M, West GB (2004). Towards a metabolic theory of ecology. Ecology 85: 1771-1789.
14. Calder WA 3rd (1981). Scaling of physiological processes in homeo-thermic animals. Annu Rev Physiol 43: 301-322.
15. Calder WA 3rd (1984). Size, Function and Life History. Harvard University Press: Cambridge, MA.
16. Callan WM, Sunderman FW Jr (1973). Species variations in binding of 63 NI(II) by serum albumin. Res Commun Chem Pathol Pharmacol 5: 459-472.
17. Clark B, Smith DA (1984). Pharmacokinetics and toxicity testing. Crit Rev Toxicol 12: 343-385.
18. Clarke D, Burchell B (1994). The uridine diphosphate glucuronyosyl- transferase multigene family: function and regulation. In: Kauff-man F (ed.). Conjugation-Deconjugation Reactions in Drug Metabolism and Toxicity. Springer-Verlag: Berlin, pp. 3-43.
19. Crozatier B, Su JB, Corsin A, Bouanani N.E.-H. (1991). Species differences in myocardial beta-adrenergic receptor regulation in response to hyperthyroidism. Circ Res 69: 1234-1243.
20. Davis LE, Westfall BA (1972). Species differences in biotransformation and excretion of salicylate. Am J Vet Res 33: 1252-1262.
21. Dedrick R, Bischoff KB, Zaharko DS (1970). Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother Rep 54: 95-101.
22. Duncan RP, Forsyth DM, Hone J (2007). Testing the metabolic theory of ecology: allometric scaling exponents in mammals. Ecology 88: 324-333.
23. Edginton AN, Theil FP, Schmitt W, Willmann S (2008). Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol 4: 1143-1152.
24. Edwards NA (1975). Scaling of renal functions in mammals. Comp Biochem Physiol A 52: 63-66.
25. ESG (2006). Expert Scientific Group on Phase One Clinical Trials Final Report. HMSO: London.
26. Feng MR, Lou X, Brown RR, Hutchaleelaha A (2000). Allometric pharmacokinetic scaling: towards the prediction of human oral pharmacokinetics. Pharm Res 17: 410-418.
27. Ginsberg G, Hattis D, Russ A, Sonawane B (2004). Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophyl-line in neonates and adults: implications for assessing children's risks from environmental agents. J Toxicol Environ Health A 67: 297-329.
28. Guengerich FP (2008). Cytochrome p450 and chemical toxicology. Chem Res Toxicol 21: 70-83.
29. Haley PJ (2003). Species differences in the structure and function of the immune system. Toxicology 188: 49-71.
30. Hammerlein A, Derendorf H, Lowenthal DT (1998). Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications. Clin Pharmacokinet 35: 49-64.
31. Hill AV (1950). The dimensions of animals and their muscular dynamics. Sci Prog 38: 209-230.
32. Hollenberg NK (2000). Implications of species difference for clinical investigation: studies on the renin-angiotensin system. Hypertension 35: 150-154.
33. Hunt CM, Westerkam WR, Stave GM (1992). Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 44: 275-283.
34. Huxley JS (1932). Problems of Relative Growth. Methuen: London.
35. Ishizuka H, Konno K, Shiina T, Naganuma H, Nishimura K, Ito K et al. (1999). Species differences in the transport activity for organic anions across the bile canalicular membrane. J Pharmacol Exp Ther 290: 1324-1330.
36. Johnson TN (2003). The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children. Toxicology 192: 37-48.
37. Johnson TN (2005). Modelling approaches to dose estimation in children. Br J Clin Pharmacol 59: 663-669.
38. Johnson TN (2008). The problems in scaling adult drug doses to children. Arch Dis Child 93: 207-211.
39. Johnson TN, Rostami-Hodjegan A, Tucker GT (2006). Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 45: 931-956.
40. Jones HM, Parrott N, Jorga K, Lave T (2006). A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 45: 511-542.
41. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE (2003). Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 349: 1157-1167.
42. Khor SP, Amyx H, Davis ST, Nelson D, Baccanari DP, Spector T (1997). Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of animal data, pharmacoki-netics and toxicodynamics of 5-fluorouracil in humans. Cancer Chemother Pharmacol 39: 233-238.
43. Kirkwood JK (1983). Influence of body size in animals on health and disease. Vet Rec 113: 287-290.
44. Kleiber M (1932). Body size and metabolism. Hilgardia 6: 315-353.
45. Lack JA, Stuart-Taylor ME (1997). Calculation of drug dosage and body surface area of children. Br J Anaesth 78: 601-605.
46. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F et al. (2006). Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127: 1109-1122.
47. Lave T, Dupin S, Schmitt C, Chou RC, Jaeck D, Coassolo P (1997). Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. J Pharm Sci 86: 584-590.
48. LeCluyse E, Rowlands J (2007). Species Differences in Receptor-Mediated Gene Regulation. In: Ekins S (ed.). Computational Toxicology. John Wiley & Sons Inc.: Hoboken, NJ, pp. 71-98.
49. Leslie EM, Deeley RG, Cole SP (2005). Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204: 216-237.
50. Lin JH (1998). Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab Dispos 26: 1202-1212.
51. Lindstedt L, Schaeffer PJ (2002). Use of allometry in predicting anatomical and physiological parameters of mammals. Lab Anim 36: 1-19.
52. Lowe PJ, Hijazi Y, Luttringer O, Yin H, Sarangapani R, Howard D (2007). On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development. Xenobiotica 37: 1331-1354.
53. Maczewski M, Mackiewicz U (2008). Effect of metoprolol and ivabra-dine on left ventricular remodelling and Ca2+ handling in the post-infarction rat heart. Cardiovasc Res 79: 42-51.
54. Mahmood I (2007). Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development. Adv Drug Deliv Rev 59: 1177-1192.
55. Mahmood I, Balian JD (1996). Interspecies scaling: predicting phar-macokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. J Pharm Sci 85: 411-414.
56. Mandelbrot B (1982). The Fractal Geometry of Nature. W.H. Freeman and Company: New York.
57. Muller M, Jansen PL (1997). Molecular aspects of hepatobiliary transport. Am J Physiol 272: G1285-G1303.
58. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ et al. (1996). P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6: 1-42.
59. Nozaki Y, Kusuhara H, Kondo T, Iwaki M, Shiroyanagi Y, Nakayama H et al. (2007). Species difference in the inhibitory effect of nonste-roidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices. J Pharmacol Exp Ther 322: 1162-1170.
60. Peters SA (2008a). Evaluation of a generic physiologically based phar-macokinetic model for lineshape analysis. Clin Pharmacokinet 47: 261-275.
61. Peters SA (2008b). Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles. Clin Pharmacokinet 47: 245-259.
62. Peters SA, Hultin L (2008). Early identification of drug-induced impairment of gastric emptying through physiologically based pharmaco-kinetic (PBPK) simulation of plasma concentration-time profiles in rat. J Pharmacokinet Pharmacodyn 35: 1-30.
63. Poulin P, Theil FP (2002a). Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 91: 129-156. (Pubitemid 34074473)
64. Poulin P, Theil FP (2002b). Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci 91: 1358-1370.
65. Price EM, Lingrel JB (1988). Structure-function relationships in the Na,K-ATPase alpha subunit: site-directed mutagenesis of glutamine-111 to arginine and asparagine-122 to aspartic acid generates a ouabain-resistant enzyme. Biochemistry 27: 8400-8408.
66. Price PS, Conolly RB, Chaisson CF, Gross EA, Young JS, Mathis ET et al. (2003). Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit Rev Toxicol 33: 469-503.
67. Reagan-Shaw S, Nihal M, Ahmad N (2008). Dose translation from animal to human studies revisited. Faseb J 22: 659-661.
68. Reigner BG, Blesch KS (2002). Estimating the starting dose for entry into humans: principles and practice. Eur J Clin Pharmacol 57: 835-845.
69. Rennen MAJ, Hakkert BC, Stevenson H, Bos PMJ (2001). Data-based derived values for the inter-species extrapolation, a quantitative analysis of historical toxicity data. Comments Toxicol 7: 423-436.
70. Resetar A, Spector T (1989). Glucuronidation of 3′-azido-3′- deoxythymidine: human and rat enzyme specificity. Biochem Pharmacol 38: 1389-1393.
71. Riviere JE, Martin-Jimenez T, Sundlof SF, Craigmill AL (1997). Inter-species allometric analysis of the comparative pharmacokinetics of 44 drugs across veterinary and laboratory animal species. J Vet Pharmacol Ther 20: 453-463.
72. Rodriguez W, Selen A, Avant D, Chaurasia C, Crescenzi T, Gieser G et al. (2008). Improving pediatric dosing through pediatric initiatives: what we have learned. Pediatrics 121: 530-539.
73. Schmidt-Nielsen K (1984). Scaling: Why is Animal Size so Important? Cambridge University Press: Cambridge.
74. Shah RR (2004). Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II). Br J Clin Pharmacol 58: 452-469.
75. Sharma V, Dhillon P, Wambolt R, Parsons H, Brownsey R, Allard MF et al. (2008). Metoprolol improves cardiac function and modulates cardiac metabolism in the streptozotocin (STZ) diabetic rat. Am J Physiol Heart Circ Physiol 294: H1609-H1620.
76. Shi Q, Black TA, Gross KW, Sigmund CD (1999). Species-specific differences in positive and negative regulatory elements in the renin gene enhancer. Circ Res 85: 479-488.
77. Sinha VK, De Buck SS, Fenu LA, Smit JW, Nijsen M, Gilissen RA et al. (2008). Predicting oral clearance in humans: how close can we get with allometry? Clin Pharmacokinet 47: 35-45.
78. Smith DA (1997). Pharmacokinetics and pharmacodynamics in toxicology. Xenobiotica 27: 513-525.
79. Stanley LA, Horsburgh BC, Ross J, Scheer N, Wolf CR (2006). PXR and CAR: nuclear receptors which play a pivotal role in drug disposition and chemical toxicity. Drug Metab Rev 38: 515-597.
80. Tang H, Mayersohn M (2005a). A mathematical description of the functionality of correction factors used in allometry for predicting human drug clearance. Drug Metab Dispos 33: 1294-1296.
81. Tang H, Mayersohn M (2005b). A novel model for prediction of human drug clearance by allometric scaling. Drug Metab Dispos 33: 1297-1303.
82. Tang L, Persky AM, Hochhaus G, Meibohm B (2004). Pharmacokinetic aspects of biotechnology products. J Pharm Sci 93: 2184-2204.
83. Tobin T, Brody TM (1972). Rates of dissociation of enzyme-ouabain complexes and K 0.5 values in (Na + + K + ) adenosine triphos-phatase from different species. Biochem Pharmacol 21: 1553-1560.
84. Toutain PL (2002). Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine. AAPS PharmSci 4: E38.
85. USFDA (2005). Guidance for Industry: Estimating the Maximum Safe Starting Dose in Adult Healthy Volunteer. US Food and Drug Administration: Rockville, MD.
86. Van Miert AS (1989). Extrapolation of pharmacological and toxico-logical data based on metabolic weight. Arch Exp Veterinarmed 43: 481-488.
87. Wajima T, Fukumura K, Yano Y, Oguma T (2002). Prediction of human clearance from animal data and molecular structural parameters using multivariate regression analysis. J Pharm Sci 91: 2489-2499.
88. West GB, Brown JH (2005). The origin of allometric scaling laws in biology from genomes to ecosystems: towards a quantitative unifying theory of biological structure and organization. J Exp Biol 208: 1575-1592.
89. West GB, Brown JH, Enquist BJ (1997). A general model for the origin of allometric scaling laws in biology. Science 276: 122-126.
90. West LJ, Pierce CM, Thomas WD (1962). Lysergic acid diethylamide: its effects on a male asiatic elephant. Science 138: 1100-1103.
91. Willmann S, Hohn K, Edginton A, Sevestre M, Solodenko J, Weiss W et al. (2007). Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn 34: 401-431.
92. Woodman D (1997). Laboratory Animal Endocrinology: Hormonal Action, Control Mechanisms and Interactions with Drugs. John Wiley & Sons: Hoboken, NJ.
93. Yang F, Tong X, McCarver DG, Hines RN, Beard DA (2006). Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacoki-netic model. J Pharmacokinet Pharmacodyn 33: 485-518.